TY  - JOUR
AU  - Martin, Miguel
AU  - Brase, Jan C
AU  - Ruiz, Amparo
AU  - Prat, Aleix
AU  - Kronenwett, Ralf
AU  - Calvo, Lourdes
AU  - Petry, Christoph
AU  - Bernard, Philip S
AU  - Ruiz-Borrego, Manuel
AU  - Weber, Karsten E
AU  - Rodriguez, César A
AU  - Alvarez, Isabel M
AU  - Segui, Miguel A
AU  - Perou, Charles M
AU  - Casas, Maribel
AU  - Carrasco, Eva
AU  - Caballero, Rosalía
AU  - Rodriguez-Lescure, Alvaro
PY  - 2016
DO  - 10.1007/s10549-016-3725-z
UR  - http://hdl.handle.net/10668/9862
T2  - Breast cancer research and treatment
AB  - There are several prognostic multigene-based tests for managing breast cancer (BC), but limited data comparing them in the same cohort. We compared the prognostic performance of the EndoPredict (EP) test (standardized for pathology laboratory) with...
LA  - en
KW  - Breast cancer
KW  - Chemotherapy
KW  - EndoPredict
KW  - PAM50
KW  - Prognosis
KW  - Antineoplastic Agents, Hormonal
KW  - Breast Neoplasms
KW  - Chemotherapy, Adjuvant
KW  - Female
KW  - Humans
KW  - Kaplan-Meier Estimate
KW  - Prognosis
KW  - Receptor, ErbB-2
KW  - Receptors, Estrogen
KW  - Risk Assessment
KW  - Treatment Outcome
TI  - Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study.
TY  - research article
VL  - 156
ER  -